數九寒冬，冰天雪地，不可能戶外鍛煉。咋辦？大冬天也不能涼拌啊，那就“躲進小樓成一桶，管它包子與饅頭”，一個字：吃！

效果顯著，這些天俺真成了一桶：飯桶。
剛來美國時，俺很能吃苦。現在呢？“很能吃苦”四個字，俺仍然做到前三個。

到了這個年齡，代謝能力下降，但胃口依然很“執着”，可謂吃啥長啥，吃多少長多少。每次上完廁所興沖衝上秤一稱...... 結果，都會讓我對物質守衡定律產生懷疑。

所以，現在每天在treadmill上揮汗如雨，在游泳池隨波逐流，都是為了能夠減肥。而減肥的目的，則是為了更盡情地吃。

最近，發現一個不用鍛練身體的減肥妙招，跟大家分享一下：

買Hims & Hers 股票！

有懂行的吃爪群眾會問，這家公司不是賣仿製減肥藥的嗎？想減肥，應該買它的減肥藥才對呀。

自打Hims & Hers的CEO勇敢地站出來，公開表態反對以色列在加沙的genocide之後（全美國成千上萬的上市公司，有膽量公開表態的，廖廖無幾，costo算另一家），股票就一直跌跌不休，從72跌到了21，跌到讓股民懷疑人生。

不過，你懂得。

屋漏偏逢連夜雨，現在這家公司又吃上了侵權官司，還被FTC調查..... 如此以往，恐怕要跌成毛票，一錢不值了。

借一個被高位套牢的股友的原話：

“買了HIMS 股票以後已經瘦了好幾公斤，比它們家的冒牌減肥藥有用多了。”

瞧瞧，不僅效果顯著，而且笑果顯著。

所以，牆裂建議想減肥的朋友們，趕緊的，在HIMS跌成毛票之前，梭哈all in，絕對會有奇佳的減肥體驗。

Hims & Hers stock has dropped due to slowing growth, increased competition, regulatory pressure over compounded weight-loss drugs (like semaglutide), and a strained relationship with major drugmakers like Novo Nordisk, impacting their lucrative GLP-1 business and leading to concerns about future profitability and sustainability, despite ongoing strong operational performance.
Key Reasons for the Stock Decline:
Regulatory Uncertainty & GLP-1 Market Changes: The FDA's shift in stance on the semaglutide shortage, once a key driver for Hims & Hers' cheaper compounded alternatives (like Wegovy/Ozempic), has created revenue uncertainty and margin pressure.
Slowing Growth & Competition: Analysts note a significant slowdown in revenue growth from triple digits to more sustainable rates, coupled with rising customer acquisition costs and intense price competition, particularly in the men's sexual health sector.
Novo Nordisk Conflict: Novo Nordisk's termination of a direct partnership and its efforts to curb compounded sales have negatively impacted Hims & Hers' ability to sell these popular weight-loss drugs.
Operational & Profitability Concerns: Broader operational complexities from expanding into compounding and lab testing, alongside potential margin compression, raise near-term performance worries for some analysts.
FTC Investigation: Ongoing scrutiny from the Federal Trade Commission (FTC) on their marketing and practices adds another layer of investor caution.
Context for Investors:
While the company shows strong fundamentals, the market is recalibrating after unsustainable hyper-growth, making it look expensive to some.
Some analysts believe the sell-off might present a buying opportunity, given the company's long-term potential despite these headwinds.